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Abstract
Progression of chronic kidney disease (CKD) is a major health issue due to persistent accumulation of extracellular matrix
in the injured kidney. However, our current understanding of fibrosis is limited, therapeutic options are lacking, and
progressive degradation of renal function prevails in CKD patients. Uncovering novel therapeutic targets is therefore
necessary. We have previously demonstrated reversal of renalf i b r o s i sw i t hl o s a r t a ni ne x p e r i m e n t a lh y p e r t e n s i v e
nephropathy. Reversal was achieved provided that the drug was administered before late stages of nephropathy,
thereby determining a non-return point of CKD progression. In the present study, to identify factors critically involved in
the progression of renal fibrosis, we introduced losartan at the non-return point in L-NAME treated Sprague Dawley rats.
Our results showed either reversal or progression of renal disease with losartan, defining 2 groups according to the
opposite evolution of renal function. We took advantage of these experimental conditions to perform a transcriptomic
screening to identify novel factors potentially implicated in the mechanisms of CKD progression. A secondary analysis of
selected markers was thereafter performed. Among the targets identified, periostin, an extracellular matrix protein,
presented a significant 3.3-fold higher mRNA expression in progression compared to reversal group. Furthermore,
independent of blood pressure, periostin was strongly correlated with plasma creatinine, proteinuria and renal blood
flow, hallmarks of hypertensive renal disease severity. Periostin staining was predominant in the injured regions, both in
experimental hypertensive and human nephropathy. These results identify periostin as a previously unrecognized
marker associated with disease progression and regression in hypertensive nephropathy and suggest measuring
periostin may be a sensitive tool to evaluate severity, progression and response to therapy in human kidney disease
associated to hypertension.
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Introduction
In the kidney, sustained insult commonly leads to an increased
synthesis of extracellular matrix, which surrounds and eventually
replaces the injured structures. In chronic kidney diseases, this
fibrotic process spontaneously autoaggravates and contributes to a
progressive reduction in the number of functioning nephrons,
irrespective of the initial cause of the disease [1,2]. Therefore,
understanding mechanisms responsible for the progression or the
reversal of fibrosis is a major therapeutic target. Over the past
decade, several key contributors to the pathophysiology of fibrosis
have been identified, including components of the renin-
angiotensin-aldosterone system, transforming growth factor-beta1
(TGF-beta1), regulators of cell plasticity, and proinflammatory
cytokines such as monocyte chemoattractant protein-1 (MCP-1)
[3,4]. Recent studies have also underlined the importance of
extracellular matrix proteins, not only as components of the
fibrotic scar, but also as active regulators of tissue remodeling via
cell-matrix signaling [5–7].
We have previously demonstrated the possibility of therapeutic
reversal of renal fibrosis in experimental hypertensive nephropa-
thy, especially with losartan, an angiotensin II receptor antagonist
[8–10]. Fibrogenesis is a multistep process and therapeutic efficacy
requires timely treatment. Specifically, the introduction of losartan
beyond a non-return point of experimental renal fibrosis fails to
achieve control of the profibrotic mechanisms.
In the present study we hypothesized that actors crucially
involved in the orientation of disease at the non-return point may
play an important role in the pathophysiology of renal fibrosis, and
may consequently be useful biomarkers of ongoing injury and
promising therapeutic targets. To identify candidate proteins we
performed a transcriptomic analysis of factors associated with the
progression of chronic kidney disease. Thereafter, we further
characterized selected targets at different stages of hypertensive
nephropathy, including progression and reversal of renal disease
after introduction of losartan. We concluded that periostin
expression more than indices of endothelial or tubular dysfunction
was strongly related to the progression and the regression of
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31974experimental hypertensive nephropathy, independently of changes
in systolic blood pressure.
Results
Pharmacological nitric oxide inhibition induces
progressive renal vascular disease
After initiation of L-NAME treatment, rats rapidly developed
severe persistent hypertension (MAP=21167 mmHg, and
21265 mmHg at 6 and 10 weeks treatment respectively)
(Table 1). Progressive hypertensive renal disease was characterized
by the early onset of proteinuria (1.360.2 g/mmol creatininuria at
week 6) and a delayed increase in creatininemia (100614 mmol/l
at week 10). Renal blood flow exhibited a striking reduction from 6
weeks L-NAME treatment onwards. As expected, these functional
alterations were associated with progressive histological lesions of
vascular nephropathy including glomerulosclerosis, vascular fibro-
sis, interstitial fibrosis, tubular lesions and inflammation (Figure 1,
Table 1). A characterization of the inflammatory infiltrating cells
showed that CD3+ lymphocyte count was strongly increased after
6 and 10 weeks L-NAME treatment (Figure 2, Table 1).
Losartan promotes regression of renal disease in a
subpopulation of LNAME-treated rats
To study determinants of renal disease progression/regression,
hypertensive rats displaying standardized mild nephropathy
(proteinuria/creatininuria ,1 g/mmol) were treated with losar-
tan, together with the continuation of L-NAME. Important
heterogeneity in the evolution of renal disease was observed.
Rats were thereafter separated in two groups according to the
median value of plasma creatinine after 4 weeks losartan+L-
NAME treatment (Figure S1). Accordingly, the ‘‘No Regression’’
(No Reg) group presented an escape of renal disease with a
significantly higher plasma creatinine compared to the ‘‘Regres-
sion’’ (Reg) group, which exhibited reversal of renal disease
(Table 1). Consistent with the differential therapeutic efficiency of
losartan between the 2 groups, No Reg rats presented aggravated
renal blood flow, vascular lesions, glomerulosclerosis and renal
inflammation compared to Reg group (Figure 1, Table 1).
Periostin is closely associated with the progression/
reversal of experimental hypertensive nephropathy
Transciptomic analysis was performed in a limited number
(n=4) of animals from the No Reg and Reg groups comparing the
expressions of 180 genes involved in fibrosis, extracellular matrix
regulation and inflammation. Table S1 shows the genes that were
significantly upregulated. Among them, periostin showed the
highest overexpression and since it was not reported before to be
involved in renal disease, we investigated in subsequent studies
more precisely its expression.
As shown by RT-qPCR, periostin was expressed in the rat
kidney at baseline and was 13- and 18-fold up-regulated after 6
and 10 weeks L-NAME, respectively (Figure 3A). Importantly
periostin mRNA was significantly blunted in Reg group, whereas
No Reg group presented a persistent increase in periostin
expression in spite of 4 weeks losartan treatment (Figure 3A).
Immunostainings revealed a weak expression of periostin in the
normal rat kidney, within the media of arteries and arterioles.
Hypertensive nephropathy was characterized by a strong increase
in periostin staining in the media and the adventitia of renal
vessels. Interestingly periostin also exhibited a focal de novo
interstitial expression in close vicinity to the most severe vascular,
glomerular and tubular lesions (Figure 4).
To evaluate the importance of periostin as a marker and/or an
actor of kidney disease progression, we performed regression
analyses with hallmarks of hypertensive nephropathy severity as
dependent variables. We found a very strong association between
periostin mRNA expression and plasma creatinine (r=0.68,
p,0.001), proteinuria (r=0.71, p,0.001) and renal blood flow
(r=20.64, p,0.001) (Figure 3B, Table 2). Periostin presented
stronger associations with the latter dependent variables when
compared to classical players of the proinflammatory and
profibrotic process involved in hypertensive nephropathy
(Table 2). Of note, when systolic blood pressure was added as
an independent variable in multiple regression analyses the
Table 1. Descriptive statistics for functional and structural parameters of hypertensive nephropathy.
C LOS LN 6w LN 10w LN reg LN no reg
Functional parameters
MAP (mmHg) 128641 1 8 69 21167
*# 21265
*# 16765
* 20265
*#
P/C (g/mmol) 0.1660.03 0.1760.02 1.3160.24
*# 0.9560.13
*# 0.3060.02 0.4560.06
*
pCr (mmol/l) 43624 3 626 4 68 100614
*# 50627 6 63
*#
RBF (ml/min) 10.160.3 10.560.4 4.460.5
*# 3.360.4
*# 8.860.4 6.460.5
*#
Histological scores
Interstitial Fibrosis 0.360.2 0.260.1 0.660.3 2.160.4
*# 0.760.2 1.160.2
*
Vascular Fibrosis 0.260.1 0.260.2 0.660.2 1.660.3
*# 0.460.2 1.360.2
*#
Glomerulosclerosis 0.160.1 0.260.3 0.660.2 1.460.4
*# 0.360.1 1.060.2
*#
Tubular Lesions 0.160.1 0.160.2 0.560.2 1.860.4
*# 0.460.1 0.860.2
*
Inflammation 0.460.2 0.360.3 1.460.5
*# 2.260.4
*# 0.660.1 1.960.2
*#
CD3+ cells/mm
2 6616 625 3 66
* 100614
*# 3766
* 67612
*#
C: Control, LOS: Losartan, LN: L-NAME, LN Reg: L-NAME Regression, LN No Reg: L-NAME No Regression.
MAP: Mean Arterial Pressure, P/C: Proteinuria/Creatininuria, pCr: Plasma Creatinine, RBF: Renal Blood Flow.
N for each group is shown in Figure 3. Values are mean 6 SEM.
*p,0.05 vs C:
#p,0.05 vs LN Reg.
doi:10.1371/journal.pone.0031974.t001
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(p,0.001) and renal blood flow (p,0.05) held true.
In contrast with periostin, markers of endothelial
dysfunction, epithelial mesenchymal transition or fibrillar
collagen synthesis did not discriminate between
regressive or not regressive experimental nephropathy
Since endothelial injury is present in hypertension and may play
a central role in the pathophysiology of renal vascular diseases, we
investigated the transcriptional regulation of ET-1 propeptide and
E-selectin in this model (Figure 5A and 5B). Interestingly, both
markers presented a strong but transient induction at week 6,
suggesting early endothelial dysfunction. However, neither E-
selectin, nor ET-1 enabled to discriminate Reg group from No
Reg group during the progression of the disease.
Although significant fibrosis was detected on week 10, but not
on week 6 (Table 1), Col3A1 RT-qPCR was already up-regulated
on week 6, indicating persistently increased synthesis of collagen
from this stage onwards (Figure 5C). Note that Col3A1 synthesis
was not different between Reg and No Reg groups. Vimentin was
progressively induced at week 6 and week 10 (Figure 5D). In
contrast to Col3A1, vimentin exhibited a sharp decrease after the
initiation of losartan, irrespective of the Reg/No Reg group.
Periostin is overexpressed in human chronic renal
allograft
To determine whether the latter findings may translate to
human disease, we further analyzed periostin immunostaining on
human kidney biopsy specimens. Periostin was not expressed in
glomeruli or tubules in normal renal tissue. Only a weak staining
could be found in small vessels (Figure 6A, 6B). Chronic allograft
nephropathy is a clinical condition characterized by tubulointer-
stitial inflammation and fibrosis. In this condition we observed an
intense periostin expression, predominantly in the region present-
ing tubular atrophy and interstitial fibrosis, as well as in several
tubular epithelial cells (Figure 6C, 6D). Using serial sections with
periostin and vimentin, the latter indicating epithelial phenotypic
changes associated with renal graft fibrosis progression, the
expression of periostin was mainly located in the interstitial area
around the injured tubules, suggesting the importance of periostin
expression during human kidney injury (Figure 6E, 6F).
Discussion
The renin-angiotensin system is a central player in multiple
mechanisms responsible for the progression of renal fibrosis [11–
13]. Timely blockade with ACE inhibitors, renin inhibitors or
AT1 receptor antagonists can promote reversal of renal lesions
and ultimately prevent the evolution towards end-stage organ
failure in experimental models of renal disease [9,10,14].
However, renin-angiotensin system blockers are inconstantly
efficient in preventing chronic renal disease progression, particu-
larly in humans, although the factors involved in this variable
efficacy remain unclear [1,15].
In this study we analyzed the reversal of L-NAME hypertensive
nephropathy with losartan, and focused on the identification of
markers of a non-return point of renal disease reversal. Our results
show that losartan ameliorated renal hemodynamic alterations,
proteinuria, and vimentin expression in all groups treated,
compared to L-NAME 6w and 10w groups. Since these variables
are classical determinants of renal disease progression, it could
have been expected that the latter effects would be associated with
a global protection against the functional and structural alterations
ultimately induced by NO-deficiency hypertension. Instead, in
spite of these beneficial effects, the No Reg group presented severe
Figure 1. Masson’s trichrome staining of renal cortex. Original
magnification 620.
doi:10.1371/journal.pone.0031974.g001
Figure 2. CD3 immunohistochemistry in renal cortex. Original
magnification 620.
doi:10.1371/journal.pone.0031974.g002
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creatinine and vascular fibrosis similar to LN 10w group.
Important additional factors implicated in renal disease progres-
sion and influenced by losartan are therefore responsible for the
differential evolution between the Reg and No Reg groups. The
reason why these important factors were different between the two
groups is uncertain. In spite of the standardized cut-off point
chosen to introduce losartan, we cannot exclude that the
heterogeneity observed between Reg and No Reg groups may
be due to subtle differences in the evolution of the renal disease
around the non-return point, when losartan was introduced.
Alternatively, preexisting heterogeneity in the regulation of pro- or
anti-fibrotic genes between the Sprague Dawley rats, an outbred
strain in which genome is not totally identical between animals,
could account for the differences between the Reg and No Reg
groups. We took advantage of these original experimental
conditions to perform a transcriptomic analysis of selected markers
associated with the progression of hypertensive nephropathy.
In the Reg group, rats presented reduced renal fibrosis
compared to the No Reg group. Renal fibrosis is characterized
by the accumulation of extracellular matrix, including fibrillar
collagen. Since collagen III production, evaluated by Col3A1 RT-
qPCR, was not different between the Reg and No Reg groups, the
histological differences observed may be due to increased
degradation of fibrillar collagen, as previously described in our
laboratory [9].
L-NAME hypertension is associated with features of endothelial
dysfunction [16–18]. Our results show early endothelial activation
indicated by increased expression of ET-1 propeptide and E-
selectin in LN 6w group. We and others have previously identified
ET-1, a potent profibrotic vasoconstrictor, as a mediator of renal
fibrosis in hypertensive nephropathy [10,19]. E-selectin is an
endothelial inducible adhesion molecule notably involved in the
pathophysiology of atherosclerosis and in renal ischemia-reperfu-
sion, but its potential implication in hypertensive nephropathy has
not been reported previously. Although the present study shows
early increase in renal ET-1 and E-selectin mRNA, their similar
expressions in Reg and No Reg groups suggest that these markers
of endothelial activation are not major determinants of the reversal
of renal disease induced by AT1 receptor blockade. Similarly,
vimentin, a classical marker of mesenchymal cells associated with
fibrogenesis, was reduced by losartan treatment, irrespective of the
reversal of renal disease.
Periostin is an extracellular matrix protein first identified in the
periosteum and the periodontal ligament [20]. Angiotensin II can
induce periostin expression in fibroblasts and vascular smooth
muscle cells, via Ras/p38 MAPK/CREB and ERK1/2/TGF-
beta1 pathways and via phosphatidylinositol-3-kinase signaling,
Figure 3. Periostin expression is correlated to the progression of renal disease. (A): Real-time quantitative PCR for periostin renal mRNA
expression. Results are expressed as arbitrary units. Error bars represent SEM. * p,0.05 vs C;# p,0.05 vs LN Reg. (B–D)Logarithmic regression
between renal periostin mRNA and plasma creatinine, proteinuria/creatininuria, and renal blood flow.
doi:10.1371/journal.pone.0031974.g003
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ischemic, hypertensive and hypertrophic cardiomyopathies, and
an AT1 receptor antagonist decreases the cardiac expression of
periostin [23–25]. In the kidney, experimental studies evaluating
the implication of periostin in physiology and disease are scarce.
Periostin is transiently expressed during renal development [26],
and the expression in the normal adult kidney is low. Recent
studies observed overexpression of periostin in animal models of
diabetic, renal subtotal ablation and ureteral obstruction nephrop-
athies [27]. In humans, periostin staining was observed in biopsies
of glomerular diseases and within the cysts in autosomal dominant
polycystic kidney disease [28,29]. In addition, increased urinary
excretion rates of periostin were reported in a limited number of
proteinuric and non-proteinuric CKD patients [27]. Whether
periostin is implicated in hypertensive nephropathy and in the
progression/reversal of chronic kidney disease remained un-
known.
Our results identified a progressive induction of periostin in the
kidney with the progression of the hypertensive nephropathy.
Regression analyses found a strong association between periostin
mRNA expression and robust functional markers of kidney
disease. Importantly, these associations held true when systolic
blood pressure was added as a covariate, which suggests that
periostin is correlated to renal injury independently of the degree
of hypertension. Immunohistochemical analyses revealed that the
localization of periostin was predominantly perivascular, in areas
where important deposits of extracellular matrix occur in this
model. We also observed an intense predominantly extracellular
staining for periostin in the injured fibrotic tubulo-interstitial
regions of chronic allograft nephropathy, which further demon-
strates overexpression of periostin in human kidney disease.
Identification of the main cells responsible for the interstitial
accumulation of periostin requires further investigation. Data from
previous studies suggests that fibroblasts, smooth muscle cells and
tubular epithelial cells may be involved in periostin expression in
this setting [21,22,30].
We found that after the onset of hypertensive renal disease,
curative treatment with losartan was associated with diminished
periostin expression in Reg, not in No Reg group, which suggests
that the reduction of periostin may be implicated in the
mechanisms of angiotensin II-related disease progression and that
reduction of periostin expression may be a critical determinant of
disease reversal. Interestingly, the analysis of histological fibrosis
scores shows that the difference between Reg and No Reg groups
was most evident for perivascular fibrosis, in accordance with
periostin distribution in experimental hypertensive nephropathy.
These original data suggest that periostin may be related to the
pathophysiology of extracellular matrix accumulation at the site of
renal injury.
Together, the results of this work identify periostin as a
previously unrecognized marker associated with hypertensive
nephropathy. Further research is necessary to precise the potential
of renal, plasma and urine periostin as prognostic biomarkers to
monitor the progression and therapeutic control of human chronic
kidney diseases.
Materials and Methods
Animal treatment
Male Sprague-Dawley rats, weighing 250 g, were maintained
on a normal-salt diet and had free access to chow and tap water.
NO synthesis was inhibited by L-NAME (orally,
15 mg.kg
21.day
21). We have previously found that this dose
produced a gradual elevation of blood pressure accompanied by
the progression of renal disease. As shown in Figure S1, when
proteinuria exceeded 1 g/mmol creatinine (,6 weeks), a group of
animals was killed to allow estimations of renal hemodynamics and
morphological parameters just before the beginning of therapy
(LN 6w group, n=10). The remaining animals were divided into
Figure 4. Expression of periostin by immunohistochemistry in
renal cortex during L-NAME-induced hypertensive nephropa-
thy. Original magnification 620.
doi:10.1371/journal.pone.0031974.g004
Table 2. Univariate regression analyses between kidney
disease progression hallmarks (as dependent variables) and
renal cortex mRNA expression of selected genes (as
independent variables).
Plasma
Creatinine
Proteinuria/
Creatininuria
Renal Blood
Flow
Periostin 0.68*** 0.71*** 20.64***
Col1A2 0.41** 0.57*** 20.45**
Col3A1 0.42** 0.36* 20.41*
MMP2 0.52*** 0.32 20.32
Vimentin 0.63*** 0.67*** 20.59***
MCP-1 0.22 0.22 20.22
VCAM-1 0.38* 0.20 20.30
ESel 0.40* 0.47** 20.33*
ET-1 0.38* 0.51*** 20.61***
All variables were log-transformed, except from Renal Blood Flow which
exhibited normal distribution.
Values are r coefficients.
*p,0.05;
**p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0031974.t002
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the first subgroup, L-NAME was given alone (LN 10w group,
n=12); in the second subgroup treatment was accompanied by the
oral administration of an AT1 receptor antagonist (losartan,
30 mg.kg
21.day
21 in drinking water, Merck Sharp and Dohme-
Chibret). At the end of losartan treatment, we separated the
animals of the second group in two subgroups: animals with
creatininemia below (LN Reg, n=14), and above or equal to the
median value (LN No Reg, n=15). The doses of the drugs were
based on pilot experiments and previously published studies
[8,30]. Control animals were sacrificed at 6 and 10 weeks. Since
control animals presented similar results for all measured
parameters, pooled data are presented (C group, n=8). Three
animals received losartan during 4 weeks as additional control
group (LOS group, n=3). All protocols and treatments were
performed with the approval of the French government ethics
committee.
Renal hemodynamics
After anesthesia by pentobarbital sodium (50–60 mg/kg
intraperitoneally, Nembutal, Abbott, Chicago, IL), animals were
placed on a servo-controlled table kept at 37uC and the trachea
was cannulated to facilitate respiration. The left femoral artery was
catheterized for measurement of invasive arterial pressure, and a
femoral venous catheter was used for infusion of volume
replacement. An ultrasound transit-time flow probe (1RB,
Transonic, Ithaca, NY) was placed around the left renal artery.
Bovine serum albumin (4.7 g/dl of saline solution) was infused
initially at 50 ml/min to replace surgical losses, and then at 10 ml/
min for maintenance. Arterial pressure was measured via a
pressure transducer (Statham P23 DB); RBF was measured by a
flowmeter (T 420, low-pass filter, 40 Hz, Transonic). RBF values
were controlled for zero offset determined at the end of an
experiment after cardiac arrest. Data were recorded, stored, and
Figure 5. Markers of endothelial dysfunction, epithelial mesenchymal transition and fibrosis during progression/regression of
renal disease. Real-time quantitative PCR for endothelin-1 (ET1, A) and E-selectin (ESel, B) Col3A1 (C) and vimentin (D). Results are expressed as
arbitrary units. Error bars represent SEM. * p,0.05 vs C;# p,0.05 vs LN Reg.
doi:10.1371/journal.pone.0031974.g005
Figure 6. Periostin immunohistochemistry in normal human
kidney (A, B), and chronic allograft nephropathy (C, D). Original
magnification 640. Periostin (E) and vimentin (F) staining on serial
sections in chronic allograft nephropathy. Original magnification 620.
doi:10.1371/journal.pone.0031974.g006
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the IOX software (EMKA Technologies, Paris, France).
Urinary protein excretion and plasma creatinine
Morning urine samples were collected over a standardized 4-h
period. Urinary protein concentration was normalized to creati-
nine concentration, and values were expressed as g protein per
mmol creatinine. Central venous blood samples were withdrawn
on the last day of the study, and plasma creatinine (mmol/l) was
measured by automated Jaffe’s method.
Renal histology
Kidneys were stained with Masson’s trichrome solution. Four-
mm sections of kidneys were examined on a blinded basis by two
investigators independently to estimate inflammation, tubular
lesions, interstitial fibrosis, vascular fibrosis, glomerular sclerosis
and vascular necrosis using a 0 to 4 injury scale as described
previously [7,8]. Lesion indexes from individual sections were
averaged to calculate a sclerotic index for each rat.
Immunohistochemistry for CD3
Four-micrometer-thick sections of paraffin-embedded kidneys
were dewaxed, heated in citric acid solution (pH 6) at 98uC for
30 min, and incubated first with a polyclonal goat anti-rat CD3
antibody recognizing T lymphocytes (Santa Cruz Biotechnology,
Santa Cruz, CA) for two hours at 37uC and then incubated for
30 min at room temperature with a second antibody from N-
Histofine kit (Nichirei Biochemicals, Japan). Staining was revealed
by applying AEC (Dako), counterstained with hematoxylin QS
(Vector, Burlingame, CA), and finalized with Permanent Aqueous
Mounting Media (Innovex). Quantification of CD3-positive cells
was performed using Olympus analysis software.
Immunohistochemistry for periostin and vimentin
On rat tissue, 4-mm thick frozen sections were incubated with
polyclonal rabbit anti-rat periostin antibody (Abcam, Cambridge,
UK) overnight at 4uC and then incubated for 30 min at room
temperature with a second antibody from N-Histofine kit (Nichirei
Biochemicals, Japan).Staining was revealed by applying AEC (Dako),
counterstained with hematoxylin QS (Vector, Burlingame, CA), and
finalized with Permanent Aqueous Mounting Media (Innovex).
Renal biopsies from patients (1 normal kidney, 1 chronic
allograft nephropathy) were retrospectively analyzed. Informed
consent was given for use of part of the biopsy for scientific
purpose. All procedures and use of tissue were performed
according to the national ethical guidelines and were in
accordance with the declaration of Helsinki. Paraffin-embedded
sections were dewaxed and hydrated. The antigens were retrieved
by 20-min boiling in 10 mM citric acid solution (pH 6). The
sections were incubated overnight with 1/4000 anti-periostin
polyclonal rabbit antibody (Biovendor, France) or 1/1000 anti-
vimentin mouse monoclonal antibody V9 (Zymed, Invitrogen,
Cergy Pontoise, France). The sections were then incubated with
anti-rabbit or anti-mouse antibody conjugated with peroxydase-
labeled polymer (Dako, Trappes, France). Immunoreactive
proteins were visualized with a 3-amino-9-ethylcarbazole-contain-
ing peroxydase kit (Dako) and counterstained with hematoxylin.
For negative controls, the primary antibody was replaced by an
equal concentration of rabbit or mouse IgG.
Real Time quantitative PCR and Transcriptomic Analysis
We extracted RNA from the renal cortex and the abdominal
aorta using TRIzol solution (Life Technologies BRL, Gaithers-
burg, MD). RNA quality was checked by measuring the ratio of
optical densities at 260 and 280 nm and residual genomic DNA
was removed by DNase I treatment for 30 min at 37uC
(Fermentas). We used reverse transcription with Revert Aid H
minus First Strand DNA Synthesis kit (Fermentas) to convert 1 mg
RNA into cDNA. Transcriptomic analyses were performed with
RT
2Profiler PCR Array (Superarray, Bioscience Corp, Tebu Bio,
Le Perray en Yvelines, France). cDNA was amplified by PCR
using a LightCycler 480 (Roche Diagnostic) using SYBR Green
(Fast Start DNA Master SYBRGreen I; Roche Applied Science,
Roche Diagnostic), specific primers for selected mRNA and
hypoxanthine-guanine phosphoribosyltransferase (HPRT) as
housekeeping gene under the following conditions: 95uC for
5 min, and 45 cycles at 95uC for 15 s and 60uC for 15 s, then
72uC for 15 s. Specific primers were designed by Universal Probe
Library system (UPL, Roche Applied Science), sequences are
shown in Table 3. To normalize the qRT-PCR results we used
Roche LightCycler 2.0 software (Roche Diagnostics). We
expressed results as 2
2DCp, where Cp is the cycle threshold
number. We analyzed dissociation curves after each run for every
amplicon to assess the specificity of quantification when using
SYBR Green.
Statistics
Statistical analyses for the in vivo studies were performed using
ANOVA followed by Fisher’s protected least significance differ-
ence test in the Statview software package. All values are means 6
SEM. Univariate and multivariate regression analyses between
selected mRNA qRT-PCR values and quantitative surrogate
markers for kidney disease progression were computed after log
Table 3. Primers used for qRT-PCR.
mRNA Strand Sequence
Periostin Sense 59- TCGTGGAACCAAAAATTAAAGTC - 39
Antisense 59- CTTCGTCATTGCAGGTCCTT - 39
Col3A1 Sense 59- CAAGGCTGAAGGAAATAGCAA - 39
Antisense 59- TGCTCCATTCACCAGTGTGT - 39
Col1A2 Sense 59- CCTGGCTCTCGAGGTGAAC - 39
Antisense 59- CAATGCCCAGAGGACCAG - 39
MCP-1 Sense 59- AGCATCCACGTGCTGTCTC - 39
Antisense 59- CACCCACAGTGGACATAGCA - 39
VCAM-1 Sense 59- CAAATGGAGTCTGAACCCAAA - 39
Antisense 59- GGTTCTTTCGGAGCAACG - 39
MMP2 Sense 59- GCACCACCGAGGATTATGAC - 39
Antisense 59- CACCCACAGTGGACATAGCA - 39
ESel Sense 59- AGGCTTCAGTGTGGTCCAA - 39
Antisense 59- CAAGGCTTGAACACTGTACCC - 39
Vimentin Sense 59- TTCTTCCCTGAACCTGAGAGA - 39
Antisense 59- GAGTGGGTGTCAACCAGAGG- 39
TGF-beta1 Sense 59- CCTGGAAAGGGCTCAACAC - 39
Antisense 59- CAGTTCTTCTCTGTGGAGCTGA - 39
ET-1 Sense 59- TGTCTACTTCTGCCACCTGGA - 39
Antisense 59- CCTAGTCCATACGGGACGAC - 39
HPRT Sense 59- GACCGGTTCTGTCATGTCG - 39
Antisense 59- ACCTGGTTCATCATCACTAATCAC - 39
doi:10.1371/journal.pone.0031974.t003
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with p,0.05 were considered statistically significant.
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